TissueGene, Inc. Presents Phase 2 Data For Its Novel Cell Therapy For The Treatment Of Osteoarthritis Of The Knee

ROCKVILLE, Md., May 11, 2015 /PRNewswire/ -- TissueGene Inc. is pleased to announce that Dr. Moon Jong Noh, VP of Research & Development, will present phase 2 clinical data for TG-C at both the 12^th World Congress of the International Cartilage Repair Society (ICRS) and the 18^th meeting of the American Society of Gene & Cell Therapy (ASGCT).  Dr. Noh presented a poster at ICRS on Saturday May 9^th, and he will follow with an oral presentation at ASGCT on Friday May 15^th. 

TG-C is an allogeneic (donor) cell therapy involving human chondrocytes (cartilage cells) that have been genetically modified to produce the therapeutic growth factor TGF-beta1 and has been developed to induce cartilage regeneration in patients with osteoarthritis.  In a primary analysis of the phase 2 clinical study results, TG-C showed a statistically significant improvement over placebo in the change from baseline in both pain (VAS) and function (IKDC) scores. The MRI analysis showed cartilage regeneration evidence in selected TG-C treated patients. On the basis of this compelling phase 2 data, TissueGene is preparing to initiate phase 3 trials of TG-C in patients with osteoarthritis of the knee.

About TissueGene, Inc.

TissueGene Inc. is a biopharmaceutical company based in Rockville, Maryland, specializing in regenerative therapies for the treatment of various orthopaedic diseases. Founded in 1999, TissueGene is focused on treatment through the regeneration of damaged cartilage, joints and nerves. TissueGene has completed Phase 2 trials of TG-C for an allogeneic cell therapy for osteoarthritis of the knee. Information can be found at the NIH registry, www.clinicaltrials.gov. For additional information about TissueGene, Inc., please visit the Company's website at www.TissueGene.com.

About the International Cartilage Repair Society (ICRS)

The International Cartilage Repair Society is a forum that combines scientists and clinical researchers who are interested in cartilage biology and cartilaginous tissue engineering. They create a link between the scientific laboratory work and treatments of patients in clinical settings. The ultimate goal of the ICRS is to stimulate education and research within the field of cartilage repair through regular events to create an informed society. For further information about the ICRS, please visit their site at www.cartilage.org.

About the American Society of Gene & Cell Therapy (ASGCT)

The American Society of Gene & Cell Therapy is a non-profit organization that represents researchers and scientists that have devoted their lives to the discovery of genetic and cellular therapies. Established in 1996, the ASGCT contains nearly 1,800 members worldwide.  The ASGCT works to bring together scientists, researchers, and others within the medical field to incorporate genetic and cellular therapies into the practice of medicine. For more information, please visit their site at asgct.org.

Logo - http://photos.prnewswire.com/prnh/20141107/157412LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tissuegene-inc-presents-phase-2-data-for-its-novel-cell-therapy-for-the-treatment-of-osteoarthritis-of-the-knee-300080789.html

SOURCE TissueGene, Inc.